Clinical Evaluation of Levofloxacin (LVFX) in the Treatment of Bacterial Skin Disorers

• Published in: Skin research Vol. 39; no. 5; pp. 530 - 542
• Main Authors: NAKAGAWA, Koichi, KOBAYASHI, Hiromi, FUKAI, Kazuyoshi, KONO, Takeshi, MIZUNO, Nobuyuki, HIRAI, Akiko, TERAMAE, Kayoko, TERASHIMA, Tooru, HAYASHI, Akihide, TAKEBAYASHI, Ryoko, ISHII, Masamitsu, SHINDO, Kisa, HONJO, Takako, SUZUKI, Shinsuke, KUNIYUKI, Shuichi, FUKUDA, Michio, ABE, Yoshiko, SHIMOTOGE, Masashi
• Format: Journal Article
• Language: English
• Published: Meeting of Osaka Dermatological Association 1997
• Subjects: bacterial skin infection; clinical evaluation; levofloxacin; LVFX; MIC; staphylococcus aureus
• ISSN: 0018-1390; 1884-541X
• DOI: 10.11340/skinresearch1959.39.530

To investigate the usefulness of LVFX, an open multi-center study was conducted in123 patients suffering from infectious atheroma (24 patients), furuncle (19 patients) andother acute skin infections (80 patients). Patients ranged in age from 15 to 88 years andthe mean age was 43.8 years. Before the treatment, culture specimens from the lesionswere obtained, and Staphylococcus aureus was cultured in 39 cases. The MIC90 of LVFXagainst these strains was 0.39μg/ml and its of CPFX and SPFX were 0.78 and 0.2μg/ml, respectively. The oral dose of LVFX was 300 mg/day and the duration of treatment was4 to 7 days. Results obtained were as follows; marked improvement in 58 (48%), moderateimprovement in 45 (37%) and slight improvement in 16 (13%) cases, with an efficacyrate of 84.4%. As clinical adverse reaction, nausea was seen in one patient. Thus, the final utility rate was 83.5%. The results of our study support the efficacy and safety of LVFX in the treatment ofbacterial skin disorders.